Introduction
Mastalgia causes distress, particularly since the patient often assumes that it is associated with cancer. Sleeplessness and irritability are often ascribed to it, and surgeons may be asked to provide treatment. At the Cardiff breast clinic, some 50 new patients are seen every month, and in about five of these breast pain is the sole complaint. Many clinicians think of mastalgia as part of the premenstrual syndrome, but accounts of the syndrome, although they describe the sensations of breast distension, do not highlight breast pain as a major component.' Dysmenorrhoea has been distinguished as a different clinical entity from the premenstrual syndrome.2 Other symptoms of the premenstrual syndrome are rarely present in premenopausal women presenting with mastalgia, yet 300o of our patients complain of dysmenorrhoea. Mastalgia has been defined as premenstrual breast pain associated with breast nodularity severe enough to demand active treatment,' but we have seen patients in whom the symptom occurs other than premenstrually and even after the menopause.
While weight and water fluctuations during a menstrual cycle occur in women with and without premenstrual symptoms, these increases are not invariably associated with the premenstruum.4
Furthermore, cyclical symptoms are not necessarily correlated with an increase in total body water (TBW).6 7 For example, a decrease in TBW has been reported as accompanying depression found premenstrually and at other times. 8 We have tried to clarify the role of body water in the aetiology of cyclical mastalgia by comparing body weights and TBW volumes during one menstrual cycle in patients with mastalgia and in symptom-free age-matched controls. We set out to show what changes in body weight and TBW occurred during the menstrual cycle and whether these changes were the same for patients and controls and for patients whose symptoms were always premenstrual and those who had mastalgia at other times. We also sought a correlation between mastalgia and cyclical changes in weight or water and any psychoneurotic traits, as shown by a questionnaire. solitary symptom and premenstrual tension as a syndrome is suggested by the fact that in our study of the former significant reductions in TBW during the premenstruum occurred in only five out of 39 patients, only one of whom had a depressive personality trait, while Herzberg found a significant decrease premenstrually in 11 nuns with severe premenstrual tension. Possibly diuretics taken in the premenstruum might induce depression.8 In our study no single psychoneurotic trait or cluster of traits was characterised by either an increase or a decrease in total body water. Conclusions-Although there may be some cases of cyclical mastalgia in which an increase in premenstrual water contributes to the symptom, the prescription of diuretics for most patients with this condition has no rational basis. The need for a simple means of recognising those, if any, likely to be helped by diuretics is apparent and other methods of treating the condition should be evaluated.
Methods

Introduction
Familial type II hyperlipoproteinaemia (WHO classification), an inherited metabolic disorder, is characterised by the accumulation of low-density lipoproteins transporting cholesterol in the blood. Homozygous patients have raised cholesterol levels (over 13 0 mmol/l; 502 mg/100 ml), xanthomata and vascular disease appearing at an early age. Heterozygotes also have an increased incidence of premature vascular disease, which is quantitatively more important because of the frequency of the heterozygous state.
An important rate-determining step in cholesterol biosynthesis is catalysed by 3-hydroxy-3-methylglutaryl coenzyme-A reductase (EC 1.1.1.34; HMG CoA reductase). Although most studies have used rat and mouse liver systems, available evidence indicates that this is also true in man. Thus Williams and Avigan' reported the stimulation of acetate incorporation into cholesterol in human fibroblasts and leucocytes in culture when the medium contained delipidated instead of whole serum, and suggested that this was due to induction of HMG CoA reductase. Fogelman et a12 supported this hypothesis and suggested that the greater induction of HMG CoA reductase that they observed on transferring leucocytes from patients with heterozygous type II hyperlipoproteinaemia to medium containing a low lipid concentration was due to a defective sterol-binding "repressor" in the cell. Brown et al,3 4 using fibroblasts from a homozygous patient, found defective inhibition of HMG CoA reductase activity in cells incubated with low-density lipoproteins and reported an intermediate pattern in heterozygotes. Their evidence suggested a defective binding of low-density lipoproteins to the cell membrane of fibroblasts in affected people.
We report the finding of defective regulation of HMG CoA reductase activity in leucocytes from a patient with familial heterozygous type II hyperlipoproteinaemia and present a study of this enzyme in the patient's family, showing the value of measuring the enzyme in identifying those affected.
Materials and methods
The propositus (subject II 7; see table) was investigated and treated as an inpatient. Members of his family were visited individually. Fasting venous blood samples were taken into tubes containing disodium edetate (final concentration 2 mmol/l) for cholesterol and triglyceride measurement, lipoprotein electrophoresis, and the isola-
